DaVita (DVA) Receives a Buy from Robert W. Baird


In a report released today, Matthew Gillmor from Robert W. Baird reiterated a Buy rating on DaVita (NYSE: DVA), with a price target of $90. The company’s shares opened today at $70.92.

According to TipRanks.com, Gillmor is a 5-star analyst with an average return of 15.6% and a 66.0% success rate. Gillmor covers the Services sector, focusing on stocks such as Encompass Health Corporation, Addus Homecare Corp, and Envision Healthcare.

Currently, the analyst consensus on DaVita is a Strong Buy with an average price target of $84.

See today’s analyst top recommended stocks >>

DaVita’s market cap is currently $12.55B and has a P/E ratio of 33.02. The company has a Price to Book ratio of 2.74.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DaVita, Inc. engages in the provision of medical care services. It operates through the following US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts